C3J scientists actively hunt phage from a variety of natural habitats and clinical samples. Our large library of multi-drug resistant pathogens (e.g. ESKAPE pathogens) and microbiome targets aids in identification of the optimal phage chassis for downstream engineering.
In partnership with Synthetic Genomics, C3J employs next-generation sequencing, and proprietary sequencing database and software for analysis of our phage.
C3J’s team of molecular biologists engineer desirable phenotypes to phage that enable wide host range, payload expression, biofilm degradation, resistance prevention, and bioactive peptide display.
Rounding out C3J’s bench to clinic capabilities, our 35,000 sq.ft. facility is equipped with GMP manufacturing suites enabling phage production, purification, and product release.